FASLG and lobular neoplasia: In lupus nephritis (LN), mangiferin increases the proportion of CD4+Foxp3+ Tregs and inhibits the mTOR/p70S6K pathway in FasL-deficient B6/gld mice, serving as a therapeutic agent for LN (57).